Expression of Wilms tumor gene protein (WT1) in different histologic subtypes of ovarian carcinoma

M. Zahid Hossain; Mahmuda Naznin; Swapna Majumder; Zahir Al Imran; Mohammad Rabiul Haque

doi:10.18203/2349-3933.ijam20233206

Authors

M. Zahid Hossain Department of Pathology, Rajshahi Medical College, Rajshahi, Bangladesh
Mahmuda Naznin Department of Microbiology, Rajshahi Medical College, Rajshahi, Bangladesh
Swapna Majumder Department of Pathology, Rajshahi Medical College, Rajshahi, Bangladesh
Zahir Al Imran Department of Pathology, Rajshahi Medical College, Rajshahi, Bangladesh
Mohammad Rabiul Haque Department of Pathology, Holy Family Red Crescent Medical College, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2349-3933.ijam20233206

Keywords:

Ovarian, Carcinoma, Histologic, Gene protein

Abstract

Background: Ovarian carcinoma is the seventh most common cancer among women worldwide and the eighth leading cause of death. Ovarian cancer develops in the ovary's tissues.

Methods: This cross-sectional descriptive study was carried out at the Department of Pathology, RMC and Department of Pathology, BSMMU, Dhaka, Bangladesh from July 2019 to June 2021 carried out with 31 histopathologically confirmed ovarian carcinomas. All cases were subjected to WT1 immunostaining followed by histopathological examination. The collected data were analyzed using Statistical Package for Social Sciences (SPSS) software, version-23.0. The ethical clearance of this study was obtained from the Institutional Review Board (IRB) of Rajshahi, Medical College, Rajshahi, Bangladesh.

Results: A total of 31 histopathologically confirmed ovarian carcinoma patients were included in this cross-sectional descriptive study. All cases were subjected to WT1 immunostaining followed by histopathological examination. The age of the study sample ranged from 20 to 75 years. The mean age of the respondent was 45.10±13.78 years. According to the histologic subtypes, WT1 was mainly expressed in serous carcinoma. All the serous carcinoma (16/16) showed a positive reaction for WT1. Among them, 14 cases (87.5%) showed >50% (3+) WT1 score and two (2) cases (12.5%) showed 11% to 50 % (2+) scores. Regarding endometrioid carcinoma four (4) (66.6%) of six (6) were negative whereas one (1) (16.6%) showed 1%-10% (1+) and one (1) (16.6%) showed 11%-50% (2+) WT1 scores. All the mucinous (4/4) and all the clear cell carcinoma (3/3) were negative with less than 1 % of the tumor cells stained two (2) cases of undifferentiated carcinoma were also negative. There was a significant relation between WT1 expression and different histologic subtypes of epithelial ovarian carcinoma with a p value of 0.001 (p<0.05).

Conclusions: WT1 can be applied by both the histopathologist and clinician as an effective marker regarding diagnosis and patient management.

Metrics

Metrics Loading ...

References

Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. Interdiscip Int J Am Cancer Soc. 2000;89(9):2006-17.

Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et al. Ovarian carcinoma histotype determination is highly reproducible and is improved through the use of immunohistochemistry. Histopathology. 2014;64(7):1004-13.

Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003;97(2):389-404.

Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990; 60(3):509-20.

Charles AK, Mall S, Watson J, Berry PJ. Expression of the Wilms' tumor gene WT1 in the developing human and in pediatric renal tumors: an immunohistochemical study. Mol Pathol. 1997; 50(3):138.

Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:1.

Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415-28.

Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: the value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology. 2008;248(1):148-59.

Zhao L, Guo M, Sneige N, Gong Y. Value of PAX8 and WT1 immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens. Am J Clin Pathol. 2012;137(2):304-9.

Lee GA, Hwang KA, Choi KC. Roles of dietary phytoestrogens on the regulation of epithelial-mesenchymal transition in diverse cancer metastasis. Toxins. 2016;8(6):162.

Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002; 117(4):541-5.

Arab M, Khayamzadeh M, Tehranian A, Tabatabaeefar M, Hosseini M, Anbiaee R, et al. The incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer. 2010; 47(3):322-7.

Hwang JY, Lim WY, Tan CS, Lim SL, Chia J, Chow KY, Chay WY. Ovarian Cancer Incidence in the Multi-Ethnic Asian City-State of Singapore 1968-2012. Asian Pac J Cancer Prev. 2019;20(12):3563-9.

Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. Eur J Cancer Prevent. 2003;12:191-4.

Hafedh MI, Ali SA, Talal LF. The role of Wilm’s Tumor1 immunohistochemical marker in surface epithelial ovarian tumors. J Faculty Med Baghdad. 2015;57(2):145-50.

Tanaka K, Ikeda M, Sonoo H, Hirono M, Nomura T, Ohkubo S, et al. The Relationship between Wilms' Tumor 1 (WT1) and Paired Box 8 (Pax-8) Protein Expressions in Papillary and Anaplastic Thyroid Carcinomas. Kawasaki Med J. 2007;33(1):23-33.

Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19(2):158-63.

Hashi A, Yuminamochi T, Murata SI, Iwamoto H, Honda T, Hoshi K. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol. 2003;22(4):374-7.

Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol. 2003; 27(11):1434-41.

Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, Pelletier J. Analysis of the 11p13 Wilms Tumor Suppressor Gene (WTI) in Ovarian Tumors. Cancer Invest. 1993;11(4):393-9.

Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol. 2004;23(3):200-5.

Waldstrøm M, Grove A. Immunohistochemical expression of Wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. Arch Pathol Lab Med. 2005;129(1):85-8.